Contract Pharma Manufacturing News

  1. SteinCares And Shilpa Biologicals Strike Into Licensing Agreement To Expand Access To Biosimilars Across Latin America 2/25/2026

    SteinCares, a leading specialty healthcare company in Latin America, and Shilpa Biologicals Pvt. Ltd. (SBPL), a fully integrated biopharmaceutical subsidiary of Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), announce a strategic licensing agreement to commercialize a biosimilar across Latin America.

  2. Cellipont Bioservices And Soter Bio Announce Strategic Collaboration To Support Integrated U.S. Cell Therapy Manufacturing 2/24/2026

    Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), today announced a strategic collaboration with Soter Bio, a CDMO specializing in RNA and RNA–lipid nanoparticle (LNP) manufacturing for research and GMP applications.

  3. Bora Pharmaceuticals And GSK Sign $250M Five Year Global Manufacturing Contract 2/24/2026

    This renewed collaboration reinforces the long-standing relationship between the two companies and expands the partnership, allowing GSK access to multiple sites within the Bora network, including its newest OSD site in Maple Grove, Minnesota.

  4. AbbVie Announces $380 Million Investment With Two New Active Pharmaceutical Ingredient Manufacturing Facilities In Illinois 2/24/2026

    AbbVie (NYSE: ABBV) today announced a new $380 million investment to build two new active pharmaceutical ingredient (API) manufacturing facilities at its current North Chicago, Illinois, campus. These new state-of-the-art facilities will integrate advanced manufacturing technologies with artificial intelligence (AI) to support the production of AbbVie's next-generation neuroscience and obesity medications.

  5. Minaris And Genetix Biotherapeutics Expand Manufacturing Partnership To Support Commercial Supply For LYFGENIA™ (lovotibeglogene autotemcel) 2/24/2026

    Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider, and Genetix Biotherapeutics Inc., a commercial-stage biotechnology company dedicated to delivering genetic therapies for patients with severe rare diseases, today announced an expanded manufacturing partnership to increase commercial-scale production of LYFGENIA, Genetix’s FDA-approved, one-time gene therapy for individuals 12 years and older with sickle cell disease.

  6. Minaris Announces Viral Clearance Laboratory Upgrade at Philadelphia Campus 2/24/2026

    Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider, today announced an upgrade to its Viral Clearance laboratory capabilities at its Philadelphia campus.

  7. Minaris Joins CIRM Industry Resource Partner Program 2/24/2026

    Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider, today announced that it has joined the California Institute for Regenerative Medicine (CIRM) Industry Resource Partner (IRP) Program.

  8. AtomVie Global Radiopharma Supplies First Patient Dose In Radiopharm Theranostics' Phase 1/2a Clinical Study Of 177Lu-BetaBart (RV-01) 2/24/2026

    AtomVie Global Radiopharma (AtomVie), a global leading radiopharmaceutical CDMO, announced that it has supplied the successful dosing of the first patient in Radiopharm Theranostics' First-in-Human Phase 1/2a clinical study of 177Lu‑BetaBart (RV‑01) by providing GMP manufacturing and distribution services for the radiotherapeutic drug product, after successfully developing and qualifying the radiolabeling process and analytical methods using a phase-appropriate approach that expedited IND filing.

  9. Frontier Biotech And GSK Enter Global Exclusive Licensing Agreement For Small Interfering RNA Therapeutics 2/24/2026

    Frontier Biotechnologies Inc. (hereinafter referred to as "Frontier Biotech" or "the Company") has entered into an exclusive licensing agreement with GSK, a global biopharma company.

  10. AbbVie To Invest $380M In North Chicago To Further Expand Active Pharmaceutical Ingredient Manufacturing In The United States 2/23/2026

    AbbVie (NYSE: ABBV) today announced a new $380 million investment to build two new active pharmaceutical ingredient (API) manufacturing facilities at its current North Chicago, Illinois, campus. These new state-of-the-art facilities will integrate advanced manufacturing technologies with artificial intelligence (AI) to support the production of AbbVie's next-generation neuroscience and obesity medications.